ILMN Illumina: קפיטליזציה חשבונאית

Illumina, Inc. (ILMN) is a global leader in genome sequencing that generates revenue through high-cost consumables based on the "razor-and-blade" model. This price chart, currently at 2.86, reflects pressure from antitrust regulators and the risk of cheaper alternative technologies. However, patent protection for NGS systems and the spin-off of Grail strengthen the company's position, guaranteeing revenue from its installed equipment base.

Balance sheet capitalization reflects the value of net assets, determining the real financial stability of the business net of all liabilities. Monitoring this metric allows for an assessment of the debt load and the risk of insolvency should credit conditions tighten. The dynamics of an organization's balance sheet capital help identify the hidden degradation of equity in a timely manner. For Illumina, Inc. (ILMN), this indicator confirms the reliability of a model with a high share of recurring payments for consumables. Such a base mitigates the risks of single-product dependence within the DNA sequencing segment.